BIOMARKERS BASED ON TUMOR TISSUE FOR COMBINED THERAPY WITH BEVACIZUMAB Russian patent published in 2016 - IPC A61K39/395 A61P35/00 G01N33/574 

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to oncology, and is intended for increasing survival without progression of disease in patient suffering colon or rectum metastatic cancer. For implementation of method, tissue samples are obtained from above patient, VEGFA and/or CD31 expression is determined, and Bevacizumab combined with chemotherapy schedule is administered to patient. Patient therein has higher level of VEGFA and/or CD31 relative to reference levels defined in patients with colon or rectum metastatic cancer. Said chemotherapy schedule represents oxalic platinum chemotherapy schedule. Also, in vitro method is provided for detecting patients responding or sensitive to adding Bevacizumab for treatment to chemotherapy schedule.

EFFECT: application of invention group allows to increase survival rate of patients with colon or rectum metastatic cancer without progression of disease.

15 cl, 8 dwg, 4 tbl, 1 ex